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Introduction
Several neuroprotective or neurotrophic molecules have been explored as potential treatments for PD. In particular, the neurotrophic ability of Glial cell line-derived neurotrophic factor (GDNF), a member of the Transforming Growth Factor-β (TGF-β) superfamily, as a potential treatment for PD has been extensively studied. Numerous studies report that the presence of GDNF facilitates the survival of dopamine neurons in culture (Lin et al., 1993) and protects mesencephalic primary neuronal cultures from 6-OHDA or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated cell death (Hou et al., 1996) . These results have been confirmed in vivo using rodent models of PD (Fox et al., 2001 ). GDNF appears to act preferentially on dopaminergic neurons, and even a single injection of GDNF produces a profound increase in striatal dopamine content (Grondin et al., 2003; Hoffer et al., 1994) . GDNF was effective at protecting and restoring dopaminergic neurons and terminals in both the 6-OHDA lesioned rat and MPTP-treated mouse models (Kearns and Gash, 1995; Kearns et al., 1997) . Furthermore, post-lesion infusion of GDNF was able to restore tyrosine hydroxylase (TH) activity in the striatum and improve locomotion in 6-OHDA treated rats (Hoffer et al., 1994; Tomac et al., 1995) . In addition to the pharmacological evidence in rodents, a genetic mouse with post-natal conditional knock-out of GDNF demonstrated that GDNF is indispensable for adult dopaminergic neuronal survival (Pascual et al., 2008) . Thus, GDNF appears to have robust and reproducible neurotrophic activity in the dopamine-depleted nigrostriatal tract (Nakajima et al., 2001) . There is some data to suggest that GDNF may have limited utility to rescue and protect neurons in an α-synuclein model of PD (Decressac et al, 2011; Lo Bianco et al., 2004) . However, the restorative effect of GDNF has also been replicated in NHP models of PD (Gash et al., 1996; Grondin et al., 2002; Zhang et al., 1997) . The anti-Parkinsonian action of GDNF in MPTP-treated monkeys was demonstrated with behavioral assessment using a primate-adapted version of the Unified Parkinson's Disease Rating Score (UPDRS). Postmortem TH analysis showed repair of the dopaminergic nigrostriatal system in the GDNF-treated monkeys (Gash et al., 1996; Grondin et al., 2002) .
A number of human PD trials with E. coli-derived, full-length, native GDNF (Liatermin; termed GDNFwt here) have been undertaken (Kordower et al., 1999; Nutt et al., 2001) . The method of GDNFwt administration has been the subject of much debate since the protein does not easily cross the blood-brain-barrier (BBB) and systemic administration in humans causes deleterious side effects (Zurn et al., 2001) . Intra-cerebroventricular (icv) administration of GDNFwt via an implanted catheter produced no improvements in Parkinsonism as measured by UPDRS and neuropathological evidence (Nutt et al., 2003) . Gill et al. (2003) performed a more successful clinical trial in 5 PD patients by infusing GDNF directly into the putamen via a catheter pump device. After 12 months there was a 48% improvement in activities of daily living scores in the UPDRS and a significant reduction in L-Dopa induced dyskinesia (Gill et al., 2003) . Striatal dopamine uptake was also increased in the putamen up to 18 months into the trial as assessed using functional imaging with F 18 -Dopa. After two years on GDNF infusion, the patients had a 57% improvement in their off-medication motor scores and a 63% improvement in UPDRS . Imaging and functional performance measured in one of these patients up to 36 months after cessation of therapy demonstrated sustained benefit in both of these measures (Patel et al., 2013) .
Immunohistochemical (IHC) analysis of the brain of another one of these patients 3 months after cessation of therapy showed evidence for up-regulation of TH locally at the site of GDNFwt infusion in the posterior putamen and also increased expression of the sproutassociated protein, growth associated protein 43(GAP43), in the substantia nigra, providing evidence for GDNF-induced neuronal sprouting (Love et al. 2005) . A second clinical study by Slevin and co-workers reported on the effects of 6-month unilateral intraputamenal GDNFwt infusion in 10 patients with advanced PD (Slevin et al., 2005) . Each patient was placed on a dose-escalation regimen of GDNF: 3, 10, and 30 μg/day at successive 8-week intervals, followed by a 1-month wash-out period. UPDRS total scores in the on and off states significantly improved 34 and 33%, respectively, at 24 weeks compared with baseline scores. In addition, UPDRS motor scores in both the on and off states significantly improved by 30% at 24 weeks compared with baseline scores. Thus in these small open labeled studies, GDNFwt, when delivered locally in the basal ganglia but not when administered distally via the ventricles, appeared to be sufficient to restore dopamine nigrostriatal activity and improve UPDRS scores. These small trials were followed up with a larger, randomized study (34 patients) in which GDNFwt (Liatermin) was infused into the putamen of PD patients for six months (Lang et al., 2006) . While UPDRS scores improved in those patients given GDNF, it was not significantly different from those receiving placebo. In addition, dopaminergic activity (as measured by F 18 -Dopa uptake) in the striatum of subjects given GDNF was only evident in the immediate tissue surrounding the infusion site.
The discordance between animal model data, open label trials and the randomized control trial has been a topic of much discussion. Gash et al. (2005) had previously demonstrated in Parkinsonian monkeys that the extent of GDNF coverage of the putamen predicted functional improvement. Subsequent analyses by Salvatore et al. (2006) indicated that the doses and catheter used in the Phase 2 GDNFwt trial may not have be optimal. Efforts to recapitulate the human brain distribution in monkey studies with GDNFwt administered via a catheter/pump device similar to that used by Lang et al. (2006) supported the hypothesis that lack of clinical efficacy was likely due to an insufficient coverage of the putamen, estimated to be 5-8% (Salvatore et al., 2006) . Extrapolating from data generated in NHPs, it is estimated that wider coverage of the human putamen by GDNF, on the order of 30% or more, would be a key determinant of symptomatic efficacy.
Additionally, in the Phase II clinical study with GDNFwt , 18 out of 34 patients developed anti-drug antibodies and in 4 cases these antibodies were shown to be neutralizing (Tatarewicz et al., 2007) . Neutralizing antibodies can not only limit efficacy of the drug but since GDNF is an endogenous protein with peripheral functions, it raises the possibility of blocking functions of peripheral endogenous GDNF. How GDNF reached the periphery and induced antibody formation in these patients was unclear but likely involved catheter movement, or aspects involving peripheral delivery (Tatarewicz et al., 2007) . This observation raises concerns regarding the immunogenicity of GDNFwt, which potentially could impact both efficacy and safety of the drug, although no adverse consequences were reported in the trial (Tatarewicz et al., 2007) . Finally, Piccinini et al. (2013) recently showed that GDNFwt expressed and purified from E. coli had poor stability, raising this as another limitation to GDNFwt as a therapeutic for PD, since the drug may need to reside in a pump/catheter system at body temperature for many weeks to months prior to infusion.
The goal of this study was to engineer a biologically active GDNF variant (GDNFv) with the following improved properties over GDNFwt to enhance the likelihood of producing meaningful clinical efficacy: (a) increased ability to distribute in the brain, so that delivery into the putamen via a pump/catheter system would enable coverage of a greater volume of the putamen, (b) improved chemical stability to ensure sustained activity and potentially reduce time between pump refills, and (c) reduced potential for immunogenicity and thereby decreased likelihood of anti-drug antibody formation. We characterize and report that the mammalian cell-derived GDNF variant, GDNFv, has superior properties over GDNFwt in in vitro and in vivo systems and these engineered properties make GDNFv better suited as a potential targeted regenerative therapy for PD.
Materials and methods

Expression and purification of GDNFwt and GDNFv
GDNFwt is the 134 amino acid mature wild type human GDNF (Accession number NP_000505.1), excluding the 77-residue preprosequence. GDNFΔ38 is GDNFwt with an N-terminal truncation of 38 amino acids. GDNFv differs from GDNFwt in having an N-terminal truncation of 31 amino acids and 2 amino acid substitutions at positions 38 (N38Q) and 95 (D95E) of the original GDNFwt sequence. GDNFv has the following sequence (amino acids in bold represent changes from the wild type sequence):
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSG SCDAAETTYDKILKNLSRNRRLVSEKVGQ ACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
GDNFwt was expressed in E. coli and purified using 3-step column chromatography (Huang and Ma, 2001 ). The re-folded protein was first applied to an SP Sepharose fast flow column equilibrated in 20 mM sodium acetate, pH 5. GDNFwt was eluted with an ascending linear salt gradient from 0.3 to 1 M NaCl in 20 mM sodium acetate, pH 5. The cation exchange chromatography (CEX) mainstream pool was supplemented with NaCl to a final concentration of 2.5 M and then applied to a Phenyl Sepharose HP hydrophobic interaction chromatography (HIC) column in 20 mM sodium citrate, pH 5. The HIC column was eluted with a descending linear salt gradient from 2.5 to 0 M NaCl in 20 mM sodium citrate, pH 5. GDNFwt bound tightly to the HIC column. The HIC mainstream pool was then concentrated and finally applied to a Superdex-75 column and the protein was eluted with PBS, pH 7.4. The final pool was concentrated, filtered through a 0.22 μm membrane and stored at 4-8°C for subsequent use.
GDNFv and GDNFΔ38 were expressed in Chinese Hamster Ovary (CHO) cells engineered to stably express these proteins. The genes encoding human GDNFv or GDNFΔ38 were prepared using standard molecular biology and sub-cloned into the Glutamine Synthetase (GS)-containing expression plasmid backbones (pEE12.4-based plasmids, Lonza Biologics, Slough, UK) in frame with the murine kappa signal sequence.
GDNFv was purified to homogeneity through 4-step column chromatography. Briefly, the harvested culture media containing GDNFv was first applied to an SP Sepharose fast flow column equilibrated in 20 mM sodium acetate, pH 5. GDNFv was eluted with a linear salt gradient from 0 to 1 M NaCl in 20 mM sodium acetate, pH 5. The mainstream pool was supplemented with NaCl to a final concentration of 2.5 M and then applied to a Phenyl Sepharose HP HIC column in 20 mM sodium acetate, pH 5. The HIC column was eluted with a reversed linear salt gradient from 2.5 to 0 M NaCl in 20 mM sodium acetate, pH 5. GDNFv bound weakly to the HIC column. A pool of the flow-through and early eluting fractions was then applied to a column at pH 5 that contained the multi-modal chromatography Capto MMC resin. The column was washed with 50 mM Tris-Cl, pH 8, and GDNFv was eluted with a linear salt gradient from 0 to 1 M NaCl in 50 mM Tris-Cl, pH 8. The Capto MMC mainstream was finally applied to a Superdex-75 column and the protein eluted with PBS, pH 7.4. The final pool was filtered through a 0.22 μm membrane and stored at 2-8°C for subsequent use.
GDNFΔ38 was purified to homogeneity using three chromatography steps. Briefly, the harvested culture media containing GDNFΔ38 was adjusted to pH 5.1 with 50 mM citric acid, 150 mM NaCl and applied to a Capto MMC multimodal column. The column was washed with 20 mM Tris, 100 mM NaCl pH 7, and product eluted with 0.7 M NaCl in 50 mM Tris pH 8. The mainstream pool was supplemented to 0.9 M sodium citrate and applied to a Phenyl Sepharose HP HIC column. The HIC column was eluted with a reversed salt gradient in 50 mM Tris pH 8. HIC mainstream was applied to a Superdex 75 preparative size exclusion column and eluted with PBS, pH 7.4. The SEC mainstream pool was stored at 2-8°C.
SDS-PAGE gel analysis
SDS-PAGE was performed on NuPage 4-12% BisTris Gel (Cat# NP0321-Box) with NuPage MES SDS running buffer (Cat# NP0002). Samples were prepared by combining 30 μL sample and 10 μL 4 × NuPage Sample Buffer (Cat# NP0007) (± 10 × reducing agent). Samples were heated for 5 min at 95°C. 15 μL (approximately 5 μg) of each sample was loaded into the well. Gels were run for 35 min at 200 V, rinsed 3 times over 5 min with deionized water, and stained with Simple Blue Safestain (Cat# LC6060). Gel was destained with deionized water. SeeBlue®Plus2 Pre-Stained Standard (Cat# LC5925) was used for molecular weight markers.
Stability analysis by LC/MS
To determine the chemical stability of GDNFwt and GDNFv, samples at 1.0 mg/ml in PBS buffer at pH 7 were stressed at 37°C for 4 weeks and analyzed by LC/MS to identify amino acids that may be associated with chemical instability.
Intact and partial molecular analysis
A 10 μl aliquot of each sample was mixed with 40 μg of 100 mM Tris-HCl buffer, pH8, 1.0 μg of 50 mg/ml DTT at ambient temperature for 30 min. Each sample was submitted for LC/MS analysis.
Lys-C digest
A 20 μl aliquot of each sample solution was lyophilized to dryness under a speed vacuum system and the material was then reconstituted in 0.5 μl of 50 mg/mL DTT and 4.5 μl of 6 M guanidine-HCl, 0.5 M Tris-HCl buffer, pH 8. The mixture was incubated at 37°C for 30 min and each solution was then diluted with 93 μl of water and treated with 2 μl of 0.2 mg/ml Lys-C (Wako) at 37°C for 2 h. 30 μl of the tryptic digest was treated with 0.5 μl of PNGase F at 37°C for 1 h (to assess the carbohydrate profile). The digest was acidified with 2 μl of 10% TFA in H 2 O before LC/MS analysis.
LC/MS analysis
The sample solutions were analyzed by a Waters SYNAPT mass spectrometry coupled with a Waters Acquity UPLC or a Water LCT premier mass spectrometry coupled with a Waters 2795 HPLC.
ELISA analyses
Heparin binding
Heparin (Sigma) was coated at 5 μg/ml onto heparin binding plates (BD BioSciences) according to manufacturer's instructions. Plates were blocked with 3% milk-TBS-0.1% Tween20 blocking buffer for at least 1 h at 37°C. GDNFs diluted in blocking buffer were then allowed to bind approximately 1.5 h followed by incubation with 1 μg/ml biotinylated anti-human GDNF (R&D Systems) for approximately 45 min and streptavidin-HRP (Jackson ImmunoResearch, 1:2000) for 20-30 min. Plates were developed using OPD (Sigma) as a chromogenic substrate according to manufacturer's instructions and the absorbance was read at 490 nm. GraphPad Prism software was used to calculate the EC 50 confidence range values.
Receptor binding
GFRα1 or GFRα2 (human and rat GFRα1, and human GFRα2 from R&D Systems) was coated overnight at 4°C onto Greiner Immunobind plates at 1 μg/ml in 0.05 M sodium carbonate coating buffer, pH 9.6. Plates were blocked with 3% milk-TBS-0.1% Tween20 blocking buffer for at least 1 h at 25°C and then processed as described for the heparin binding ELISA above.
GDNF antibody recognition
Equimolar amounts of GDNFwt or GDNFv were serially diluted, then coated, washed and blocked as described for the receptor binding ELISAs. 1 μg/ml biotinylated anti-human GDNF was allowed to bind approximately 1.5 h. Streptavidin-HRP was allowed to bind approximately 1.25 h. Plates were then processed as described for the heparin binding ELISA.
C-Ret phosphorylation assessment
Human cell line SH-SY5Y (ATCC) with Lentiviral over-expression of human c-Ret (Accn #: NM_020630) were maintained in growth medium of High Glucose DMEM (HyClone), 10% FBS, 1 × Anti-Anti (HyClone), 1× L-glutamine (Life Technologies), and 5 μg/ml Blasticidin (Invitrogen). For Western analysis of c-Ret phosphorylation, the cells were seeded into 6-well plates, serum starved in Low Glucose DMEM (HyClone), 0.25% BSA (Life Technologies), 1 × Anti-Anti, 1 × L-glutamine for one day, and then treated with GDNF in No Glucose DMEM (Life Technologies), 0.25% BSA, 1 × Anti-Anti, 1 × L-glutamine containing 1 μg/ml hGFRα1-Fc (R&D) for 30 min at 37°C. The cells were lysed on ice in lysis buffer of M-Per (Pierce) plus Phosphatase inhibitor cocktail 1, 2, 3 (Sigma), protease inhibitor cocktail (Sigma), and HALT protease and phosphatase inhibitor cocktail (Pierce) and the lysates were stored at − 80°C until Western blot analysis using standard techniques. The primary detection antibody was rabbit-anti-pY1016-c-Ret polyclonal (Biosource) 1:1000 or rabbitanti-c-Ret polyclonal (Bioscource) 1:200 in 3% BSA/Tris-buffered saline/Tween-20(0.1%) (TBST) followed by the secondary antibody goat-anti-rabbit-HRP (Bio-Rad) 1:3000. The blots were developed using Supersignal West Pico Kit (Pierce) according to manufacturer instructions, and exposed to Kodak Biomax XAR film. For quantitative assessment of c-Ret phosphorylation using cell-based ELISA methodology, SH-SY5Y cells overexpressing c-Ret were seeded into 96-well plates at 50,000 cells/well in growth medium, followed by one day of serum starvation, and then 30 minute treatment with medium containing 1 μg/ml hGFRα1-Fc and test GDNF. The cells were fixed by the addition of fomaldehyde (Alfa Aestra) to final concentration of 4% for 2 h and rinsed with phosphate buffered saline (PBS). The plates were blocked with Block solution (Superblock; ThermoScientific), 10% goat serum (Life Technologies), 0.3% H 2 O 2 (Sigma), 0.1% Tween-20 (Thermo), for 2 h and incubated with the primary antibody rabbit anti-Phospho-Ret Y1016 prepared 1:1000 in antibody diluent (Superblock, 5% goat serum, 0.1% Tween-20) at 4°C overnight. The plates were washed with TBST and incubated for 2 h with the secondary antibody (biotin-goat anti-rabbit IgG; Jackson ImmunoResearch) prepared 1:1000 in antibody diluent. The plates were washed with TBST and incubated with an amplification solution (streptavidin-HRP; Jackson ImmunoResearch) diluted 1:3000 in antibody diluent for 2 h at room temperature. The plates were washed with TBST and developed with Supersignal Femto Substrate (Thermo) with shaking for 1-2 min before reading on Victor Luminometer. GraphPad Prism software was used to plot the resulting data and calculate the EC 50 values.
Neurite outgrowth assay
The ability to induce neurite outgrowth in PC-12 cells was evaluated based on methods described previously for GDNF and nerve growth factor (NGF; Kamata et al., 2007; Oda et al., 2007) . GDNF activity on neurons was assessed using rat Neuroscreen-1 cells (PC12 subclone, Cellomics). The cells were maintained in F-12 K basal medium, 12.5% heat inactivated horse serum, 2.5% heat inactivated fetal bovine serum (FBS), 1 × GlutaMAX TM (Invitrogen), and 1 × Anti-Anti at 37°C, 95% humidity in collagen coated flasks. To measure neurite outgrowth, the Neuroscreen-1 cells were seeded into Collagen I 96-well plates (Biocoat) at 2000 cells per well in growth medium using only the interior 60 wells. After 24 h of cell attachment, the medium was removed and new growth medium containing GFRα1-Fc at 1 μg/ml plus GDNF diluted in an 8 point dilution series was added to the plate in either triplicate wells, or six wells per concentration. Medium plus 1 μg/ml GFRα1-Fc was included as a negative control. The plates were incubated for 4 days at 37°C, 95% humidity and then fixed by adding 45 μl 16% formaldehyde plus 4× Hoechst 33342 (Molecular Probes) to each well for 1 h at room temperature. The plates were washed twice with 1 × wash buffer from Neurite Outgrowth Hit Kit TM (Cellomics) and then washed twice with 1 × buffer from the kit. The cells were immuno-stained with the neurite outgrowth reagents from the kit according to manufacturer's instructions. The plates were loaded onto Arrayscan Instrument and analyzed using Arrayscan software and Neuronal Profiling algorithm from Cellomics. Data generated by the algorithm was processed for EC 50 calculation with Graph Pad Prism software.
Rat bio-distribution and pharmacology studies
Bio-distribution studies
Male Sprague-Dawley rats (275-300 g; Harlan UK) were anesthetized using isoflurane (3% in O 2 ). A midline incision was made on the animal's head, the scalp and underlying tissue were reflected and the skull was dried to visualize bregma. Coordinates for the caudate nucleus were measured from bregma and dural surface for infusion of GDNF (Anterior-Posterior + 0.5, Lateral Medial − 3.0, DorsalVentral − 5.5 mm). A 33-gauge infusion cannula was slowly lowered to this position, and the infusion commenced 1 min later (using a pump). A 2 μl bolus of the GDNFwt or GDNFv was infused into the left hemisphere over 4 min at 0.5 μl/min (total dose 1 μg), and the cannula remained in place for a further 3 min once the infusion ceased. Once the cannula had been removed the incision site was closed, a post-operative analgesic was administered, and then the animal was allowed to recover in a temperaturecontrolled cage. At an appropriate interval following the infusion, the animal was sacrificed and the brain removed and frozen pending cryosectioning for immunohistochemistry.
Cryosectioning of the frozen rat brains began with trimming to discard the olfactory bulbs as well as the cerebellum, rostral and caudal to the infusion track. 8 μm-thick sections were taken at 300 μm intervals and placed on positively charged glass microscope slides. GDNF IHC was performed on full coronal sections at the same stereotaxic level as used for needle infusion. The slides are then placed into 4% paraformaldehyde at room temperature for 20 min and rinsed in TBST washing buffer. Using a staining solution at room temperature, the slides were incubated for 10 min with Dual endogenous enzyme block (Dako), rinsed with TBST washing buffer, incubated for 15 min each of Avidin and Biotin block (Dako), washed with TBST washing buffer, blocked with Protein block (Dako) for 30 min and blown off the slide using an air knife. Biotinylated anti-human GDNF (R&D Systems) or a biotinylated goat IgG (Dako) was diluted in Antibody Diluent with background reducing agents (Dako) to 2 μg/ml and incubated on the slide for 60 min, then rinsed with TBST washing buffer 3 times. The slides were incubated with labeled streptavidin biotin 2 (Dako) for 10 min and rinsed with TBST washing buffer. The slides were incubated with DAB + (1drop of DAB in DAB diluents) (Dako) for 5 min, rinsed and then counterstained with hematoxylin. Slides were allowed to dry and then analyzed using Aperio XT to quantify biodistribution. Images of the slides were acquired at the 20× magnification setting on an Aperio ScanScope XT (running v10.00.00.1805 of the Controller software). Meta data about the slides was tracked in Aperio's web-based software, Spectrum (v10.0.1346 Spectrum (v10.0. .1806 .
Image analysis was completed by manually outlining the brain section which included the injection track for each rat using Aperio's image viewer software, ImageScope (v10.0.36.1805) . Each outlined region was analyzed using Aperio's "Positive Pixel Count" algorithm (v9) [with all the parameters kept at their default settings, except Image Zoom = .01 and Intensity Threshold WEAK (Upper Limit) = 235]. The GDNF distribution area in mm 2 for each rat was computed by summing the positive and strong positive areas output from the positive pixel algorithm. A paired Student's t-test was used to determine statistical significance.
Dopamine turnover studies in normal rat brains
Rats were infused with 1 μg GDNFv or GDNFwt into the caudate nucleus of the striatum as described above. At an appropriate interval following the infusion the animal was sacrificed, the brain removed and the striatum accurately dissected, weighed and frozen pending HPLC analysis of dopamine and metabolites.
The frozen tissue was allowed to thaw quickly and was homogenized in 0.5 ml of homogenization buffer (0.1 M PCA, 0.1 mM EDTA, 2.5 mg/L ascorbic acid) before centrifugation at 20,000 g for 15 min. The supernatant was removed and filtered through a syringeless filtration device (Mini-uniprep, Whatman). Analysis of dopamine (DA), dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) was carried out using HPLC coupled to electrochemical detection. 20ul of each sample was injected (Triathlon, Spark Holland, Netherlands) and quantified against an external calibration curve (LC4C, BAS, USA). Mobile phase consisted of 100 mM NaH 2 PO 4 , 100 mM H 3 PO 4 , 2 mM OSA, 1 mM EDTA, 13% MeOH, pH2.8 using a BDS Hypersil 150 x 3.0 mm C18 3u particle column at 40°C (Thermo Scientific). Data was collected using Empower chromatography software (Waters). A 4-parameter logistic fit was performed on all data prior to expression as ng/g wet weight tissue. The dopamine turnover measure was expressed as (DOPAC + HVA)/DA and comparisons performed with left hemisphere (treated) versus right hemisphere (intact).
Rat 6-OHDA model of PD In order to confirm that GDNFv infused into the rat was able to reduce a neurotoxin-mediated deficit we tested its effects on DA and DA metabolites in the rat substantia nigra 21 days after a partial/retrograde 6-OHDA lesion. 10 μg of 6OHDA (Sigma Aldrich) dissolved in 2 μl of vehicle was infused into the left striatum 30 min prior to infusion of 10 μg of GDNFv, GDNFwt or vehicle in 2 μl using similar infusion parameters and methodology as described above. 21 days following the infusion the animals were sacrificed, the brains removed and the striatum and the substantia nigra accurately dissected, weighed and analyzed for dopamine and metabolites using HPLC methods as described above.
Predicted immunogenicity
Analysis was conducted by Antitope Ltd. (Cambridge UK). Samples were tested against PBMCs from a cohort of 53 healthy donors representing the world population (based on human leukocyte antigen (HLA) allotypes). Bulk cultures were established using CD8+ depleted PBMCs. CD4 + T cell responses were measured using proliferation assays ([3H]-Thymidine uptake) at days 5, 6, 7, and 8 days after addition of samples. IL-2 cytokine secretion was measured after eight days. Samples were tested at saturating concentrations (0.3 μM) which are sufficient to stimulate T cell responses. Humanized anti-A33 antibody (humanized A33) was used as a clinical benchmark control (Welt et al., 2003) .
Results
GDNFv
Full length wild type human GDNF produced in E. coli is termed GDNFwt. GDNFv is a modified form of wild type human GDNF, engineered to improve its biological and biochemical properties and produced in mammalian cells. It has an N-terminal 31 amino acid truncation and 2 conservative amino acid substitutions (N38Q, D95E) compared to GDNFwt. The full amino acid sequence of GDNFv is given in the Materials and methods section. GDNFΔ38 is a mammalian cell-derived wild type human GDNF with a 38 amino acid N-terminal truncation. SDS-PAGE analysis of GDNFwt purified from bacterial cells and GDNFv purified from CHO cells indicated greater than 95% purity (Fig. 1) .
GDNFv has reduced heparin binding activity
The 31 amino acid N-terminal deletion in GDNFv removes a large portion of the known heparin binding domain of GDNF (Alfano et al., 2007) and so would be expected to reduce the heparin binding capability of GDNFv. GDNFΔ38 is expected to show little or no binding to heparin (Piltonen et al., 2009 ). Representative heparin binding data for GDNFv, GDNFwt and GDNFΔ38 are shown in Fig. 2A . In this particular experiment, GDNFwt had an EC 50 of 0.2 nM whereas as expected, GDNFΔ38 had no detectable heparin binding. GDNFv bound heparin with an EC 50 of 28.2 nM, approximately 100 fold lower than GDNFwt, but retained detectable heparin binding activity compared to GDNFΔ38. The differential heparin binding observed between GDNFwt and GDNFv molecules was reproducible across multiple independent experiments, with 95% confidence range for the EC 50 being 0.2-0.4 nM for GDNFwt and 19.8-41.3 nM for GDNFv (n = 10 experiments for GDNFwt, n = 3 for GDNFv). The absence of heparin binding observed for GDNFΔ38 was also reproducible in independent experiments.
GDNFv maintains its ability to bind GDNF receptor GFRα1
Diffusible or soluble (non matrix-bound) GDNFs, such as those infused into the brain as therapeutics, signal through the c-Ret receptor complex by first binding to GFRα1 (Bespalov et al., 2011; Jing et al., 1996) . Binding of GDNFv to GFRα1was assessed as a first measure of its biological activity. As exemplified in Fig. 2B , GDNFv retained similar binding to human GFRα1 as GDNFwt (EC 50 for GDNFwt 0.2 nM vs GDNFv 0.3 nM). Similar GFRα1 receptor binding was observed between GDNFwt and GDNFv in multiple independent experiments, with EC 50 ranges of 0.3-0.4 nM (n = 8) and 0.3-1.9 nM (n = 4), respectively. To support in vivo efficacy testing in the rat it was also important to demonstrate that GDNFv maintained its binding to rat GFRα1 (Fig. 2C) . Again, the binding of GDNFv and GDNFwt for rat GFRα1 were similar (EC 50 for GDNFwt 0.3 nM vs GDNFv 0.6 nM, n = 2 experiments). In contrast, GDNFΔ38 showed pronounced, reproducible loss of GFRα1 binding to both rat and human forms to the extent that an EC 50 could not be calculated (results of 2 independent experiments).
GFRα2 is the main signaling receptor for the GDNF family member, neurturin (Jing et al., 1997 ), which has been tested in the clinic in a gene therapy paradigm for PD (Marks et al., 2010) . GDNFwt shows some binding to GFRα2 (Jing et al., 1997) , which led us to investigate binding of GDNFv to human GFRα2. As shown in Fig. 2D , the binding of GDNFv to human GFRα2 was markedly and reproducibly reduced compared to GDNFwt, with EC50s of 9.7 and 0.16 nM, respectively.
GDNFv induces c-Ret phosphorylation
GDNF, upon binding to GFRα1, induces association with the transmembrane receptor c-Ret leading to activation of the c-Ret tyrosine kinase and auto-phosphorylation of c-Ret on a number of residues (Jing et al., 1996) . The ability of GDNFv to phosphorylate c-Ret compared to GDNFwt was examined as a proximal signaling event downstream of receptor binding. This was a critical test for GDNFv activity as previous work had demonstrated that single mutations within GDNF could negatively impact GDNF c-Ret phosphorylation (Eketjall et al. 99 ). Treatment of c-Ret overexpressing SH-SY5Y cells with GDNFwt or GDNFv showed a dose-dependent increase in levels of phosphorylated c-Ret by both molecules (Fig. 3A) as assessed by immuno-blotting. Total c-Ret levels were not changed in response to treatment and no c-Ret phosphorylation was observed in the absence of GFRα1-Fc, indicating the dependency on GFRα1 for Ret-dependent GDNF signaling. For a quantitative analysis, c-Ret phosphorylation was analyzed using a cell-based ELISA in the same human SH-SY5Y-c-Ret overexpressing cells. Cells treated with GDNFv in the presence of GFRα1-Fc showed a dose dependent increase in c-Ret phosphorylation which was in line with that observed with GDNFwt (Fig. 3B) . The observed activities for the GDNF molecules were reproducible in multiple experiments (n = 3) with a 95% confidence range for the EC 50 being 5.1-16.0 ng/ml for GDNFv and 11.7-25.8 ng/ml for GDNFwt.
GDNFv induces neurite outgrowth in vitro
One of the relevant neurotrophic actions of GDNF on neurons is its ability to induce neurite outgrowth (Trupp et al., 1995) . Hence, Rat Neuroscreen-1 cells (NS-1), a PC-12 cell line subclone, were treated with a range of doses of GDNFv or GDNFwt for four days and the percentage of neurons in a field of extending neurites (Percent Neurons bearing neurites) calculated. The cells displayed a dose dependent response to GDNF in the induction of neurite outgrowth as shown in Fig. 3C . GDNFv and GDNFwt molecules had very similar activities in this assay with EC 50 95% confidence ranges of 1.3-2.0 ng/ml for GDNFv and 1.6-3.2 ng/ml for GDNFwt, which were reproducible across multiple (n = 4) independent experiments. Another parameter measured in this assay was Total Neurite Length per neuron which produced EC 50 values in the same ranges as those described for the parameter Percent Neurons Bearing Neurites (data not shown).
GDNFv distributes further in rat brain
It was hypothesized that the decreased heparin binding exhibited by GDNFv would translate into broader brain bio-distribution when infused in vivo. To test this hypothesis, acute bio-distribution of GDNFv was assessed by immunohistochemistry (IHC) at 3, 6, 24, 48 or 72 h after a bolus infusion into the caudate nucleus of the rat brain (n = 5 per time point). Prior to conducting IHC analyses, we confirmed that GDNFwt and GDNFv were recognized equally by the primary anti-GDNF antibody used for the IHC analyses (Fig. 4A) . No signal was seen on brain slices without primary antibody. The quantitative assessment of brain bio-distribution for the GDNFv and GDNFwt groups is summarized in Fig. 4B . Representative images of the brain IHC are shown in Fig. 4C . Beginning at 3 h post infusion, the first time point examined in this study, it was clear that GDNFv distributed over a wider area than GDNFwt. This effect was sustained for both the 6 and 24 h time-points and for all 3 initial time points this effect was statistically significant. Quantitative analysis showed that GDNFv distributed 1.5 fold more than GDNFwt at 3 and 24 h and 1.9 fold at 6 h post infusion. Since GDNFv appeared to have distributed beyond the borders of the brain, as evident by strong staining at the boundaries of the brain particularly at the 24 h time point, the observed distribution of GDNFv is likely an underestimate of the calculated distribution. By 48 and 72 h post infusion both GDNFwt or GDNFv immunoreactivity had dissipated within the rat brains. At these time points a difference in bio-distribution between GDNFv and GDNFwt was no longer observed.
GDNFv increases dopamine turnover in the rat brain
In order to confirm that GDNFv maintained biological activity in vivo as well as in vitro we took advantage of the previously reported effects of GDNF on dopamine (DA) turnover in the rat striatum (Hoffer et al., 1994) . The effect of GDNFwt and GDNFv (1 μg) on DA turnover was assessed at 3-21 days after a unilateral bolus infusion into the caudate nucleus of intact rat brain using the untreated, contralateral striatum as the baseline control. The amount of GDNF that was infused (1 ug) was sufficient to cover the majority of the striatum at early time points (Figs. 4B and C) . Both GDNFv and GDNFwt significantly increased dopamine turnover in the treated hemisphere, as compared to the intact hemisphere at 3, 7 and 10 days post infusion (Fig. 5) . No significant differences were observed between GDNFv and GDNFwt groups. Once GDNF signaling has been activated, pharmacodynamics actions such as DA turnover are sustained long after the GDNF immunostaining has waned (Figs. 4B, C) . We conclude that the long term effects on DA turnover in a small rat brain are similar between wt and variant. However, we believe in large brain systems (like the monkey and human brain) there would be an increase area and volume of activation that would separate the GDNF variant from wtGDNF. This was not possible to measure in the small rat striatum as even with low doses of infusion we are covering the whole rat striatum as can be seen in the images on Fig. 4 . In the current rat studies effects on DA turnover for either compound were no longer detectable at day 15 and day 21 post infusion.
GDNFv is efficacious in 6-OHDA rat model of PD
In order to confirm that GDNFv infused into the rat was able to reduce a neurotoxin-mediated deficit we tested its effects on DA and DA metabolites in the rat substantia nigra 21 days after a partial 6-OHDA lesion. Administration of 6-OHDA into the caudate nucleus of male rats resulted in a significant decrease in DA (Table 1) and DOPAC and HVA levels (Table 2) in the caudate nucleus and the substantia nigra on the treated side compared to the intact side. Administration of GDNFv and GDNFwt but not vehicle (Phosphate-buffered saline; PBS) into the caudate nucleus 30 min after lesion induction resulted in a significant prevention of the DA and improved the DA metabolite deficit in the substantia nigra. As we only administered an acute infusion of GDNFwt and GDNF variant and this 6-OHDA model has very severe effect on the striatal terminals we did not observed a significant rescue of the toxicity in the caudate nucleus in these studies. However, these neurochemical effects in this model were consistent across our studies and are in agreement with literature reports of neurotrophic actions of GDNF in 6-OHDA models (Kearns and Gash, 1995; Kearns et al., 1997) .
GDNFv has increased chemical stability
The chemical stability of GDNFwt and GDNFv were analyzed by LC/MS. When GDNFwt was stressed at 37°C for 4 weeks, a number of chemical degradation sites were identified as summarized in Table 3 . Since the N-terminal 31 amino acids are disordered in GDNFwt (Eigenbrot and Gerber, 1997; Parkash et al., 2008) significant oxidation and deamidation were found in this region of the molecule. In addition, Asn38 and Asp95 also showed significant deamidation (~20%) and isomerization (~14%), respectively after incubation at 37°C for 4 weeks. GDNFv with its 31 amino acid N-terminal deletion and Asn38Gln and Asp95Glu substitutions has significantly enhanced chemical stability compared to the GDNFwt, with no significant chemical instability observed after 4 weeks at 37°C. Substitution Asn38 with Gln and Asp95 with Glu eliminated deamidation and isomerization observed at Asn38 and Asp95 in GDNFwt.
GDNFv has decreased predicted immunogenicity
One of the goals of the engineering of GDNFv was to reduce the risk of clinical immunogenicity compared to GDNFwt. One way to assess the potential risk of clinical immunogenicity is to examine antigen-induced CD4 + T cell immune responses (proliferation and IL2 secretion) in PBMCs collected from volunteers representing the world's MHC haplotypes. This analysis was completed for both GDNFwt and GDNFv using Antitope's EpiScreen technology. EpiScreen™ time course T cell assays provide a format in which the immunogenicity of whole proteins can be assessed in vitro (Baker and Jones, 2007) . GDNFwt induced positive T cell proliferation responses in 23% of the samples, while GDNFv induced responses in 9% of the population. The clinical benchmark positive control induced a frequency of T cell proliferation in the study cohort (23%) that was consistent with the typical range observed in previous studies (20-30%). The results obtained for the test samples in the IL-2 ELISpot assay were similar to those obtained in the proliferation assay. GDNFwt induced responses in 30% of samples while GDNFv induced responses in 13%.
Discussion
Here we describe the engineering, mammalian expression of a GDNF variant (GDNFv) and its in vitro/in vivo characterization and comparison to GDNFwt. Overall, the data presented here demonstrate that GDNFv has significantly improved drug-like properties as compared to GDNFwt, while retaining pharmacological activity and neurotrophic efficacy similar to those of GDNFwt. First, GDNFv showed significantly greater brain bio-distribution than GDNFwt when injected as a bolus into the rat striatum. Second, GDNFv retained in vitro pharmacological properties critical for the growth factor's signaling cascade: GFRα1 binding as well as signaling via GFRα1 to induce c-Ret phosphorylation. Third, in a functional cellular assay indicative of neurotrophic activity, GDNFv induced neurite outgrowth at an EC 50 similar to that of GDNFwt. Fourth, the functional, in vivo pharmacologic activity of GDNFv monitored via striatal dopamine turnover in the rat was similar to that produced by GDNFwt. Fifth, the in vivo neurotrophic activity of GDNFv was directly demonstrated in the rat 6-OHDA lesion model, where GDNFv was, again, comparable to GDNFwt. Sixth, the in vitro chemical (Gill et al., 2003; Slevin et al., 2005) . However, a larger, randomized, controlled Phase 2 study of GDNF (Liatermin) failed to reach the primary endpoint of symptomatic benefit assessed via UPDRS (Lang et al., 2006) . Insufficient coverage of the human putamen under the dosing and delivery paradigm used is one factor that may have contributed to the failure to see efficacy in the Phase 2 study. A study in NHPs that sought to mimic the infusion conditions and catheter used in the Phase 2 trial suggested that coverage of the putamen was likely only between 2-9%, and this may have limited efficacy (Salvatore et al., 2006) . Studies with GDNF in a non-human primate (NHP) model of PD have suggested that coverage of 30% or more of the putamen may be necessary to show symptomatic efficacy on motor functions . Other factors may also have contributed to failure of the Phase 2 study including generation of neutralizing antibodies in a subset of patients, and poor chemical stability of the drug. GDNFv, a GDNF molecule that is optimized to overcome all these specific limitations of the native GDNF molecule, may be ideally suited to experimentally validate the neurotrophic activity of GDNF in Parkinsonian patients.
GDNF naturally binds to heparin sulfate proteoglycans (HSPGs) present in brain ECM, which limits its distribution upon infusion, even when using the technique of convection-enhanced delivery (CED) to boost coverage (Piltonen et al., 2009 ). Since GDNF is a potent neurotrophic factor this is likely a natural mechanism to control activity and allow only local action. That HSPG ECM binding is central to the limited bio-distribution of GDNF infusions was clearly demonstrated by Hamilton et al. (2001) who showed much greater coverage of the brain when heparin was co-administered with GDNF, presumably by competing out binding of infused GDNF to brain ECM. A stretch of 16 amino acids within the N-terminal unstructured domain of GDNF had been shown to contain one of the major heparin binding sites for GDNF since removal of this domain reduced the ability of the mutated GDNF to bind to a heparin column without affecting its ability to induce neurite outgrowth in PC-12 cells in culture (Alfano et al., 2007) . Similarly, Piltonen et al. (2009) demonstrated that an N-terminal 38 amino acid truncation of GDNF (GDNFΔ38) had dramatically reduced heparin binding while maintaining pharmacological activity in vitro, as measured by mitogen-activated protein kinase (MAPK) activation in a fibroblast cell line. However, these authors showed that GDNFΔ38 was less efficacious in vivo than native GDNF leading them to speculate that some binding to heparin sulfate proteoglycans in vivo is beneficial for the neuroprotective effects of GDNF. This raised the possibility that a partial reduction in heparin binding may be optimal. When the first 31 amino acid is removed in GNDFv, significant reduction in heparin binding (~100-fold) was observed, but some heparin binding is still maintained, consistent with the report by Parkash et al. (2008) . In a GDNF mutein with 34 amino acids truncated at the N-terminus, Arg35, Lys37 and Arg39 and Lys84 were found to interact with the heparin mimic sucrose octasulfate (Parkash et al., 2008) . The reduction in heparin binding exhibited by GDNFv compared to GDNFwt translated into increased brain bio-distribution, presumably due to reduced binding to ECM components. When GDNFv was acutely infused into the striatum of the rat brain and levels assessed by IHC at various time points post infusion, GDNFv covered 1.5-1.9 fold greater area than GDNFwt for up to 24 h post infusion. The observed distribution of GDNFv is likely to be an underestimate since GDNFv immunoreactivity reached the edges of the brain and likely some was lost through diffusion beyond the brain parenchyma. It is anticipated that the increase in brain bio-distribution evident in the rat brain would translate into meaningful increases in total volume of distribution when delivered into the human putamen. Although further truncation of the N terminus results in a further reduction in heparin binding activity, as evidenced by a mutein with an N terminal deletion of 38 amino acids (GDNFΔ38), a noticeable undesirable impact on GFRα1 binding was detected in our study. Piltonen et al. (2009) showed reduced in vivo efficacy with GDNFΔ38 compared to GDNFwt, also suggesting that removal of more than 31 N-terminal amino acids from GDNF may not be advantageous.
GDNF is a head-to-tail disulfide-bonded dimer of two 15 kD monomers with three intra-molecular disulfide bonds. The GDNF molecule that has been used in all large animal and clinical studies reported to date is an E. coli-produced version of the full-length, mature GDNF dimer. As result of bacterial expression, the molecule has an additional N-terminal methionine and is unglycoslyated. Piccinini et al. (2013) recently showed that GDNFwt purified from E. coli had poor stability compared to mammalian expressed GDNF. Since the drug may need to reside in a pump/catheter system at body temperature for many weeks to months during infusion to PD patients, we have conducted stability studies with GDNFwt and identified two major deamidation and isomerization sites, Asn38 and Asp95. Although we did not characterize the activity of these specific species, it is possible that they may have reduced activity or increased potential for immunogenicity. To consider GDNFv as a therapeutic for clinical usage, reducing heterogeneity of the material delivered to the brain is paramount. In GDNFv, Asn38 and Asp95 were mutated to Gln and Glu, respectively to improve chemical stability without impacting activity both in vitro and in vivo. The improved chemical stability of GDNFv may also translate to better chemical stability after delivery into the brain. However, we do not anticipate that these changes will increase the proteolytic stability in vivo and hence this parameter was not measured in our experiments. .GDNFv is expressed in CHO cells and is glycosylated at one position N49 (data not shown), N49 mutations to remove glycosylation in mammalian expressed GDNF resulted in significant lower expression levels, consistent with the finding by Piccinini et al (2013) . It was also observed that full length unglycosylated E. coli produced GDNFwt has significantly higher hydrophobicity than GDNFv produced by mammalian expression (data not shown). Overall, GDNFv has improved chemical stability and biophysical properties more suitable as a therapeutic compared to GDNFwt.
When considering development of an endogenous protein as a therapeutic for PD patients, even when delivery is localized to a specific brain region, it is critical that the risk of development of anti-drug antibodies be minimized. It is already known that the E. coli-produced native GDNF molecule (Liatermin) can be immunogenic as evidenced by anti-drug titers in the Liatermin Phase 2 clinical trial (Tatarewicz et al., 2007) . Proliferation and IL-2 cytokine secretion responses in ex vivo CD4 + T cell assays with a range of biologics have shown a clear correlation to the level of immunogenicity observed in the clinic. In general, protein therapeutics that induce N10% positive responses in the specific T cell assays reported here are associated with a significant risk of immunogenicity in the clinic (Jaber and Baker, 2007) . GDNFwt, as expected, was predicted to have a significant risk of immunogenicity. In contrast, GDNFv was predicted to have a low risk of immunogenicity. The reduced CD4 + T cell response of GDNFv relative to GDNFwt could be attributed to multiple factors including the source of material and the amino acid sequence composition. GDNFv lacks the 31 N-terminal amino acid residues. In addition, since GDNFv is produced from mammalian cells it is properly folded and glycosylated while GDNFwt from E coli requires refolding and is unglycosylated. As a result of these changes, GDNFv was found to be less hydrophobic compared to GDNFwt, potentially reducing its tendency to aggregate. Together these properties contribute to the predicted reduced immunogenicity risk for GDNFv in humans compared to GDNFwt.
It is important to demonstrate that GDNFv maintains its pharmacological activity. Prior evidence suggested that the N terminal region of GDNF, which is deleted in GDNFv, may not be required for GFRα1 binding (Baloh et al., 2000; Eketjall et al., 1999) and that sequences within the C terminal region of GDNF are critical for its neurogenic activity (Chen et al., 2000) . Indeed, binding of GDNFv to rat and human GFRα1 was maintained to similar levels as for GDNFwt. In vitro induction of c-Ret phosphorylation, a proximal measure of GDNF signaling, and neurite outgrowth, a key measure of neurotrophic action, were also similar between GDNFv and GDNFwt. The physiological significance of the observed reduced binding to the related receptor, GFRα2, by GDNFv compared to GDNFwt is unknown. GFRα1, the high affinity receptor for GDNF, is expressed in dopaminergic neurons in the putamen, the targeted region of the brain for GDNF therapy (Bäckman et al., 2007; Kozlowski et al., 2004) . GFRα2, however, does not appear to be expressed in the rat striatum (Kozlowski et al., 2004) . Therefore, the reduced binding of GDNFv at GFRα2 is unlikely to be of relevance for neurotrophic therapy. In fact, this property may be beneficial by helping to limit unwanted effects in other brain regions where GFRα2 is more highly and widely expressed. Since the expression of GFRα2 has not been well characterized in the human brain, the clinical relevance of this binding property remains to be determined. Taken together the in vitro properties of GDNFv suggest that the molecule has maintained the biological activity of native GDNF.
It is important that GDNFv not only maintains the biological properties of native GDNF in vitro but also in vivo. The ability to modulate dopaminergic neurochemistry and provide functional effects is an important function of GDNF in vivo (Fox et al., 2001; Grondin et al., 2003) . In concordance with the literature, GDNFwt, when infused into the caudate of normal rats, increased DA turnover significantly on the infused side as early as 3 days post infusion. The elevation in DA turnover was maintained for up to 10 days post-infusion. GDNFv was able to elicit an equivalent increase in DA turnover with a similar time course as induced by GDNFwt. The extended time course of pharmacodynamic effect of GDNFv and GDNFwt on DA turnover beyond the time when the molecules can be clearly detected in the rat brain by IHC is likely a function of downstream signaling cascade induced by c-Ret phosphorylation and has been reported previously (Durbec et al., 1996; Trupp et al., 1996) . This observation suggests that intermittent delivery of GDNF may be sufficient to produce neurotrophic responses in the brain. When the two molecules were compared for their ability to protect nigral DA and DA turnover produced by the neurotoxin, 6-OHDA, both GDNFwt and GDNFv were equally efficacious, further confirming the neurotrophic activity of GDNFv. The neurotrophic actions to the cells in the substantia nigra are consistent with retrograde transport of GDNFv and GDNFwt. It is important to note that the dose of GDNFwt and GDNFv used in the intact rat or in the 6-OHDA lesioned rat, was more than sufficient to cover the entire striatum in the rat. Hence, it was not expected that GDNFv would outperform GDNFwt in either the rat dopamine turnover study or rat neuroprotective efficacy study. It might be expected, however, that in a larger animal such as a NHP, the superior bio-distribution of GDNFv would translate into improved biological efficacy over GDNFwt. The encouraging results in the rat have led us to initiate a series of studies of GDNFv and GDNFwt in NHPs to assess brain bio-distribution, effects on DA and metabolites and motor efficacy in MPTP-intoxicated NHPs.
In summary, a novel engineered variant of GDNF, termed GDNFv, is described that has biological activity both in vitro and in vivo equivalent to GDNFwt but has the added property of increased biodistribution in the brain as well as increased chemical stability and decreased predicted immunogenicity. GDNFv may prove valuable as a targeted neuroregenerative therapy for PD.
